Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence
Authors:
- Karl-Erik AnderssonKAKarl-Erik Andersson
- Christopher R ChappleCCChristopher R Chapple
- Linda CardozoLCLinda Cardozo
- Francisco CruzFCFrancisco Cruz
- Hashim HashimHHHashim Hashim
- Martin C MichelMMMartin C Michel
- Cara TannenbaumCTCara Tannenbaum
- Alan J WeinAWAlan J Wein
- 1 July 2009
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 19 (4) , 380-394
Abstract
Treatment options for the overactive bladder were recently discussed at the 4th International Consultation on Incontinence (ICI) held in Paris, 5-8 July 2008. This article will overview current thoughts on the pharmacological and clinical basis for the different classes of drugs currently used for the treatment of lower urinary tract symptoms/overactive bladder syndrome/and detrusor overactivity. Individual drugs are not discussed in detail; particular consideration is given to therapeutic aspects of the management of the elderly patient. An extensive literature review confirms the rationale for using antimuscarinic drugs, and that the currently used drugs are efficacius with an acceptable tolerability and safety. In patients resistant to antimuscarinics, botulinum toxin may be an alternative--the vanilloids resiniferatoxin and capsaicin have very limited use. New therapeutic options with positive proof-of-concept studies, but with limited clinical experience, are beta3 adrenoceptor agonists and phosphodiesterase type 5 inhibitors. Positive signals have been found for other classes of drugs (e.g., gonadotropin-releasing hormone antagonists, neurokinin receptor-1 antagonists), but available information is not sufficient for proper assessment. Antimuscarinic drugs remain the first-line treatment of the overactive bladder and a favorable efficacy/tolerability-safety ratio can be confirmed. Promising new alternatives are emerging and future controlled studies will decide their place in the therapeutic arsenal.Keywords
This publication has 140 references indexed in Scilit:
- A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive BladderEuropean Urology, 2008
- The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-AnalysisEuropean Urology, 2008
- Store‐operated calcium entry in vascular smooth muscleBritish Journal of Pharmacology, 2008
- Characterization of a novel ATP‐sensitive K+channel opener, A‐251179, on urinary bladder relaxation and cystometric parametersBritish Journal of Pharmacology, 2007
- Impact of GPCRs in clinical medicine: Monogenic diseases, genetic variants and drug targetsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2007
- Mechanisms of Disease: involvement of the urothelium in bladder dysfunctionNature Reviews Endocrinology, 2007
- Drug-Induced Prolongation of the QT IntervalNew England Journal of Medicine, 2004
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- The Effect of Nafarelin Acetate, a Luteinizing-Hormone–Releasing Hormone Agonist, on Benign Prostatic HyperplasiaNew England Journal of Medicine, 1987
- Cardiac Antiarrhythmic Effect of Imipramine HydrochlorideNew England Journal of Medicine, 1977